Myriad Genetics (MYGN)
(Delayed Data from NSDQ)
$23.32 USD
+0.16 (0.69%)
Updated May 28, 2024 04:00 PM ET
After-Market: $23.31 -0.01 (-0.04%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$23.32 USD
+0.16 (0.69%)
Updated May 28, 2024 04:00 PM ET
After-Market: $23.31 -0.01 (-0.04%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum C VGM
Zacks News
Can EPD & Medical Devices Drive Abbott's (ABT) Q4 Earnings?
by Zacks Equity Research
Abbott (ABT) poised to ride high on continued growth in EPD and Medical Devices business in Q4.
Can ResMed (RMD) Maintain Balanced Growth in Q2 Earnings?
by Zacks Equity Research
ResMed (RMD) poised to ride high on continued growth in domestic as well as overseas business in Q2.
Myriad Genetics Fortifies Molecular Diagnostics With FDA Nod
by Zacks Equity Research
Myriad Genetics (MYGN) has been leaving no stone unturned to boost the uptake of BRACAnalysis CDx test and strengthen the Molecular Diagnostics portfolio.
AstraZeneca's Lynparza Label Now Includes Breast Cancer
by Zacks Equity Research
AstraZeneca (AZN) and Merck (MRK) announce approval of label expansion of ovarian cancer drug, Lynparza, to include HER2-/HR+ breast cancer with germline BRCA-mutation.
Teleflex (TFX), HealthTrust Rebond on Respiratory Products
by Zacks Equity Research
Teleflex's (TFX) exclusive contracts with HealthTrust provide benefits to the latter with an opportunity to consolidate its members' respiratory purchases with the same supplier.
Walgreens Closes PharMerica Buyout as KKR's Minority Partner
by Zacks Equity Research
Walgreens (WBA) along with privately-held global investment firm KKR completes the acquisition of Pharmerica for $1.4 billion. The merger agreement was announced in August.
Myriad Genetics Presents Favorable EMBRACA Trial Results
by Zacks Equity Research
Myriad Genetics (MYGN) adopts initiatives to boost uptake of BRACAnalysis CDx test.
Myriad Genetics Rides on Solid Molecular Diagnostics Suite
by Zacks Equity Research
Myriad Genetics (MYGN) adopts initiatives to boost the Molecular Diagnostics portfolio.
NuVasive (NUVA) to Acquire SafePassage, Strengthens IONM
by Zacks Equity Research
NuVasive's (NUVA) combined entity with SafePassage seems strategic as the move will fortify the NuVasive Clinical Services' (NCS) status as the largest U.S. provider of outsourced IONM services.
Quest Diagnostics Buys Fresenius Medical's Shiel Laboratory
by Zacks Equity Research
Quest Diagnostics (DGX) focuses on driving growth and operational efficiency through acquisitions.
Here's Why You Should Invest in Cooper Companies (COO) Now
by Zacks Equity Research
Cooper Companies (COO) is consistently trying to boost inorganic growth.
Genomic Health (GHDX) Oncotype DX Score Test Data Positive
by Zacks Equity Research
Genomic Health (GHDX) forges ahead with development of Oncotype DX Breast Recurrence Score test.
Boston Scientific Receives FDA Nod for Vercise DBS System
by Zacks Equity Research
Boston Scientific (BSX) forges ahead with initiatives to boost DBS portfolio under Neuromodulation business.
Smith & Nephew's Rotation Medical Deal Aids Tissue Regen Arm
by Zacks Equity Research
Smith & Nephew's (SNN) completion of Rotation Medical acquisition appears highly strategic as this will consolidate the company's position in disruptive technologies and advance its overall growth.
Hill-Rom (HRC) Banks on Strategic Buyouts, Competition Rife
by Zacks Equity Research
Hill-Rom's (HRC) upbeat long-term view buoys optimism.
Inogen Rides on Solid Product Portfolio Amid Forex Woes
by Zacks Equity Research
Inogen's (INGN) expanding product portfolio is a key catalyst. Foreign exchange headwinds continue to hurt the company's growth trajectory.
Omnicell's Rising Costs Affect Bottom Line Amid Competition
by Zacks Equity Research
Soft margin scenario is a headwind for Omnicell (OMCL). The company's strategic endeavors such as portfolio expansion, acquisitions and new market growth persistently escalate expenses.
Myriad Genetics Presents Encouraging EndoPredict Test Data
by Zacks Equity Research
Myriad Genetics (MYGN) forges ahead with initiatives to boost the Molecular Diagnostics portfolio.
NxStage Nx2me Connected Health Improves Home Hemodialysis
by Zacks Equity Research
NxStage Medical (NXTM) consistently looks to expand dialysis platform.
Cooper Companies (COO) Tops Q4 Earnings & Revenue Estimates
by Zacks Equity Research
Cooper Companies (COO) continues to witness impressive results at the CooperVision business segment that delivered strong sales in Q4.
Vertex Kalydeco Study Successful in Children Aged 1-2 Years
by Zacks Equity Research
Vertex Pharmaceuticals' (VRTX) phase III study evaluating Kalydeco in children as young as one year meets its primary safety endpoint.
Varian Halcyon Gets ANVISA Registration, Grows in Oncology
by Zacks Equity Research
Varian (VAR) consistently tries to expand in the global market with Halcyon system.
Genomic Health-Janssen Pharma Tie Up, GPS Test in Focus
by Zacks Equity Research
Genomic Health (GHDX) focuses on notable partnerships to promote its Oncotype DX Genomic Prostate Score (GPS) test.
Myriad Genetics (MYGN) Presents Positive riskScore Test Data
by Zacks Equity Research
Myriad Genetics (MYGN) presents positive riskScore data at the SABCS. With riskScore, the company intends to boost its myRisk Hereditary Cancer test suite.
Hologic's Panther Fusion Flu AdV/hMPV/RV Assay Wins FDA Nod
by Zacks Equity Research
Hologic's (HOLX) recent spree of regulatory approvals for its array of products is encouraging.